Identification of an epigenetic biomarker panel with high sensitivity and specificity for colorectal cancer and adenomas

Table 4 Promoter hypermethylation of biomarkers in colorectal adenomas (test and validation sets) compared with the patients clinico-pathological features and tumor phenotype

	CNRIP1		FBN1		INA		MAL		SNCA		Panel
	M	U	M	U	M	U	M	U	M	U	Pos	Neg
Tumors
No	101/111	10/111	77/111	34/111	39/111	72/111	93/111	18/111	59/111	52/111	103/111	8/111
Tumor phenotype
MSI	2	0	2	0	1	1	2	0	1	1	2	0
MSS	52	6	39	19	24	34	49	9	32	26	52	6
P value	NS		NS		NS		NS		NS		NS
Sex
Male	50	4	41	13	22	32	46	8	31	23	51	3
Female	51	6	36	21	17	40	47	10	28	29	52	5
P value	NS		NS		NS		NS		NS		NS
Tumor site - 2 groups
Proximal	15	2	11	6	5	12	14	3	9	8	15	2
Distal	85	7	64	28	33	59	77	15	50	42	86	6
P value	NS		NS		NS		NS		NS		NS
Tumor site - 3 groups
Right	15	2	11	6	5	12	14	3	9	8	15	2
Left	54	6	37	23	17	43	49	11	31	29	55	5
Rectum	31	1	27	5	16	16	28	4	19	13	31	1
P value	NS		7.5E-2		NS		NS		NS		NS
Dysplasia
High	7	0	5	2	2	5	7	0	5	2	7	0
Low	94	10	72	32	37	67	86	18	54	50	96	8
P value	NS		NS		NS		NS		NS		NS
Tumor size
< 10 mm	45	2	31	16	12	35	39	8	23	24	44	3
≥ 10 mm	55	7	44	18	26	36	52	10	36	26	57	5
P value	NS		NS		NS		NS		NS		NS

Pearson's chi-square and Fisher's exact tests were used to calculate P-values. Associations between SPG20 promoter hypermethylation and tumor phenotype have been published elsewhere [9].
Abbreviations: MSI, microsatellite instability; MSS, microsatellite stable; Neg, biomarker panel negative; NS, not significant; Pos, biomarker panel positive. A positive biomarker panel is defined as methylation of two or more of the following biomarkers: CNRIP1, FBN1, INA, MAL, SNCA and SPG20.

ISSN: 1476-4598